PubMed pubmed.ncbi.nlm.nih.gov [66] Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data ScienceDirect science/article/abs/pii/S0168822723001006 [67] Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data ScienceDirect science/article/abs/pii/S0168822723001006 [68] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes PubMed pubmed.ncbi.nlm.nih.gov [69] Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis ScienceDirect science/article/pii/S0753332224000313 [70] GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect science/article/pii/S2589537024003614 [71] Emerging pharmacotherapies for obesity: A systematic review ScienceDirect science/article/pii/S0031699724000024 [72] Emerging pharmacotherapies for obesity: A systematic review ScienceDirect science/article/pii/S0031699724000024 [73] Emerging pharmacotherapies for obesity: A systematic review ScienceDirect science/article/pii/S0031699724000024 [74] Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks ScienceDirect science/article/pii/S2667368124000299 [75] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [76] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ScienceDirect [77] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ScienceDirect [78] GLP-1 physiology informs the pharmacotherapy of obesity ScienceDirect [79] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ScienceDirect [80] Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks ScienceDirect [81] Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks ScienceDirect [82] Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks ScienceDirect [83] The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines PubMed pubmed.ncbi.nlm.nih.gov [84] The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines PubMed pubmed.ncbi.nlm.nih.gov [85] Emerging pharmacotherapies for obesity: A systematic review ScienceDirect [86] What is the pipeline for future medications for obesity
Prog Cardiovasc Dis
Tirzepatides are weekly injectable medications
She blends clinical experience with a practical, integrative approach
If your injection causes nausea or fatigue in the first 24 hours, a Thursday evening injection means you ride out the worst on Friday evening and Saturday morning, when you have more flexibility to rest
Similarly, a 2023 review published in Frontiers in Immunology found that GLP-1 receptor agonists reduced pro-inflammatory cytokines and oxidative stress markers across multiple tissues
